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The absence of pigment epithelium-derived factor (PEDF) in
hepatocellular carcinoma (HCC) enhances Wnt/b-catenin
signaling. Genomic proﬁling of PEDF knockout livers corre-
lates with gene expression signatures of human HCC asso-
ciated with aberrant Wnt/b-catenin signaling. PEDF is an
endogenous inhibitor of Wnt/b-catenin signaling.
BACKGROUND & AIMS: Pigment epithelium-derived factor
(PEDF) is a secretory protein that inhibits multiple tumor types.
PEDF inhibits the Wnt coreceptor, low-density lipoprotein
receptor-related protein 6 (LRP6), in the eye, but whether the
tumor-suppressive properties of PEDF occur in organs such as
the liver is unknown.
METHODS:Wnt-dependent regulation of PEDF was assessed in
the absence and presence of the Wnt coreceptor LRP6. Whole
genome expression analysis was performed on PEDF knockout
(KO) and control livers (7 months). Interrogation of Wnt/
b-catenin signaling was performed in whole livers and human
hepatocellular carcinoma (HCC) cell lines after RNA interfer-
ence of PEDF and restoration of a PEDF-derived peptide.
Western diet feeding for 6 to 8 months was used to evaluate
whether the absence of PEDF was permissive for HCC forma-
tion (n ¼ 12/group).
RESULTS: PEDF levels increased in response to canonical
Wnt3a in an LRP6-dependent manner but were suppressed by
noncanonical Wnt5a protein in an LRP6-independent manner.
Gene set enrichment analysis (GSEA) of PEDF KO livers
revealed induction of pathways associated with experimental
and human HCC and a transcriptional proﬁle characterized by
Wnt/b-catenin activation. Enhanced Wnt/b-catenin signaling
occurred in KO livers, and PEDF delivery in vivo reduced LRP6
activation. In human HCC cells, RNA interference of PEDF led to
increased levels of activated LRP6 and b-catenin, and a PEDF
34-mer peptide decreased LRP6 activation and b-catenin
signaling, and reduced Wnt target genes. PEDF KO mice fed a
Western diet developed sporadic well-differentiated HCC. Hu-
man HCC specimens demonstrated decreased PEDF staining
compared with hepatocytes.
CONCLUSIONS: PEDF is an endogenous inhibitor of Wnt/b-
catenin signaling in the liver. (Cell Mol Gastroenterol Hepatol
2015;1:535–549; http://dx.doi.org/10.1016/j.jcmgh.2015.06.006)Keywords: Extracellular Matrix; PEDF; Wnt/b-Catenin.
epatocellular carcinoma (HCC) is a major cause of
1Hcancer-related deaths worldwide. Genomic
proﬁling has classiﬁed HCC based on molecular “signatures”
that correlate with biological characteristics and clinical
outcomes.2,3 One ﬁnding from these studies is the role of the
extracellular matrix (ECM) in determining tumor behav-
ior.4–6 For instance, modulators of the ECM can activate
developmental pathways such as Wnt/b-catenin signaling,
thereby connecting liver ﬁbrosis to a signaling pathway that
drives hepatocarcinogenesis.3
Pigment epithelium-derived factor (PEDF) is a circu-
lating 50-kDa protein with ECM binding domains and
broad tumor suppressive properties.7–10 In PEDF knockout
(KO) mice, stromal abnormalities occur in multiple organs
including the prostate, pancreas, and liver.11–15 Endogenous
liver levels of PEDF decline in experimental and human
cirrhosis, and PEDF delivery ameliorates experimental liver
ﬁbrosis.14,16 PEDF null mice crossed with the KrasG12D mice
resulted in marked stromal changes in the pancreas and an
invasive malignant phenotype not seen in the KrasG12D
mutant mice alone.15 These results indicate that PEDF reg-
ulates tissue matrix quiescence and its absence is permis-
sive for malignant transformation.
The antitumor properties of PEDF are typically
attributed to an antiangiogenic effect.10,17 PEDF, however,
inhibits tumor cells in culture, indicating other mecha-
nisms.17,18 Park et al19 identiﬁed PEDF’s ability to inhibit
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Wnt coreceptor, low-density lipoprotein receptor-related
protein 6 (LRP6). Whether PEDF has systemic effects
beyond the eye and inhibits tumor development through an
inhibitory effect on Wnt/b-catenin signaling is unclear.
Because PEDF is most highly expressed by the liver, a
ﬁnding recently conﬁrmed in the Human Protein Atlas,20,21
and modulates Wnt/b-catenin signaling,19,22 we asked
whether PEDF functions as an LRP6 antagonist in the liver.
We establish that canonical Wnt3a ligand directly regu-
lates PEDF levels. PEDF, in turn, inhibits Wnt/b-catenin
signaling. Consistent with this, livers from PEDF KO mice
have a transcriptional proﬁle closely aligned with murine
models of hepatocarcinogenesis and human HCC charac-
terized by aberrant Wnt/b-catenin signaling. Knockout and
knock-in experiments demonstrate that PEDF inhibits Wnt/
b-catenin signaling in murine livers and human HCC cells
through its ability to inhibit LRP6 and b-catenin activity.
Finally, a chronic Western diet elicited sporadic HCC for-
mation in PEDF KO mice, while the human HCC specimens
demonstrated diminished PEDF staining.
Materials and Methods
Human Hepatocellular Carcinoma, Animals, and
Liver Tumor Induction
Archival human HCC tissues and their corresponding
adjacent livers from 14 patients were obtained from the VA
Connecticut Healthcare System according to an approved
institutional review board protocol. The PEDF KO mice were
bred with age-matched wild-type (WT) littermates on the
C57BL/6J background to generate heterozygous breeding
pairs, and then PEDF KO and WT offspring were back-
crossed for more than 10 generations.11 The mice were
genotyped using a commercially available polymerase chain
reaction (PCR) kit (Sigma-Aldrich, St. Louis, MO). All pro-
cedures were approved by the Institutional Animal Care and
Use Committee of VA CT Healthcare System. A commercial
Western diet—TestDiet 4342 (TestDiet, St. Louis, MO): en-
ergy (% kcal) from fat (40%), carbohydrate (44%), protein
(16%)—or standard chow was given for 26 to 32 weeks to
PEDF KO and age-matched controls (n ¼ 12/group) starting
at 8 to 12 weeks of age.
RNA Extraction and Gene Arrays
Frozen whole liver tissue from ﬁve PEDF KO animals and
WT controls were maintained in liquid nitrogen until total
RNA extraction using the TRIzol method (Invitrogen,
Carlsbad, CA). TRIzol-extracted RNA was further puriﬁed
using the Qiagen RNeasy kit (Qiagen, Valencia, CA), yielding
high-quality RNA suitable for microarray analyses (RNA
integrity number >9). The RNA quality was veriﬁed using
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto,
CA), and the RNA was quantiﬁed by NanoDrop (NanoDrop
Technologies, Wilmington, DE). For gene expression anal-
ysis, 500 ng of total RNA was used to generate biotin-
labeled cRNA using the Illumina Total RNA ampliﬁcation
and labeling kit (Ambion, Austin, TX) according to the
manufacturer’s instructions. The biotinylated cRNA waslabeled with ﬂuorescent dye at the Yale Keck Genomic Core
Facility (West Haven, CT), hybridized onto a MouseRef-8
v2.0 Expression BeadChip expression array bead chip
(Illumina, San Diego, CA) and scanned.
Expression data were analyzed by Genespring GX12
software (Agilent Technologies) after normalization by 75th
percentile shift. Only genes with a present signal (signal
above background noise) in more than 50% of samples
were included in the analysis. Group samples with gene
expression correlation coefﬁcients 0.95 were excluded
(one KO sample). For the statistical analysis, replicate
samples were averaged. Differences in gene expression
were determined using a moderated t test, and multiple
hypothesis testing adjustment was made using Benjami-
ni–Hochberg method at a false-discovery rate (FDR)  .05
and by adding a fold expression cutoff of 1.3. Genes differ-
entially expressed in KO mice versus WT were subjected to
Gene Ontology (GO) (http://www.geneontology.org) and
WikiPathways (http://www.wikipathways.org) enrichment
analysis using the hypergeometric test corrected by
Benjamini–Yekutieli method at FDR q 0.05.
To further extend the analysis, gene set enrichment
analysis (GSEA) was used (http://www.broadinstitute.org/
gsea). GSEA is a computational method that determines
whether an a priori deﬁned set of genes shows statistically
signiﬁcant differences between two phenotypes.23 To iden-
tify the gene sets that were statistically signiﬁcantly
enriched, we created a rank-order list by gene expression
differences between KO and WT sets. Gene Ontology, KEGG
pathways (http://www.genome.jp), Reactome (http://
www.reactome.org), Biocarta (http://www.biocarta.org),
Pathway interaction database (http://pid.nci.nih.gov), and
curated gene sets reﬂecting changes induced by various
chemical and genetic perturbances were used to interpret
results. FDR q value was used to rank the results. Gene sets
enriched at FDR q value  .05 and nominal P < .05 were
considered statistically signiﬁcant. Gene array data were
deposited at http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc¼GSE63643.
PEDF and PEDF Peptide Restoration
Human full-length PEDF was generated in human em-
bryonic kidney cells as described elsewhere, and its purity
conﬁrmed using Coomassie and silver staining (Invi-
trogen).12 PEDF was administered (25 mg/kg bwt) by
intraperitoneal injection on alternate days for a period of 4
weeks.24 A 34-mer of human PEDF corresponding to amino
acids 44–77 has been previously shown to inhibit neo-
vascularization and inhibit tumor growth, but its role in Wnt
signaling is unclear.17,25 We interrogated Wnt signaling with
a 34-mer that was commercially obtained (NeoBiolab,
Cambridge, MA) and used at a concentration of 100mM to
evaluate Wnt/b-catenin signaling in vitro.
Cell Culture
The human HCC cell lines HepG2 and Huh7 were
obtained from the American Type Culture Collection
(Manassas, VA), propagated, and kept at the Yale Liver
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(CM), the cells were grown to 80% conﬂuence, washed
twice with serum-free media, and then incubated with
serum-free media overnight. The CM was obtained after
18–20 hours and was concentrated approximately 40-fold
using Amicon Ultra centrifugal ﬁlters (Millipore, Billerica,
MA) with a 10-kDa cutoff. For PEDF peptide experiments,
the medium was removed, washed three times with serum
medium, and PEDF 34-mer was added for 2 hours before
the lysates were obtained. For the lysates, the cells were
scraped in radioimmunoprecipitation assay buffer contain-
ing protease and phosphatase inhibitors, incubated on ice,
and centrifuged at 10,000g for 10 minutes.Silencing of PEDF and LRP6 With RNAi in
Hepatocellular Carcinoma Cells
To reduce PEDF levels in human HCC cells, commercial
small interfering RNA (siRNA) constructs targeting PEDF
(cat. no. 4392420, 4390771) or scrambled (cat. no.
4390843) sequences (Ambion) were transfected according
to the manufacturer’s instructions. After 6 hours, the
transfection medium was replaced with fresh medium
lacking siRNA. After an additional 48 hours, the medium
was changed to serum-free medium for 24 hours. CM and
cell lysates were obtained as described earlier. The HepG2
cells stably transfected with small-hairpin RNA constructs
targeting LRP6 were a gift of Dr. Arya Mani (Yale University
School of Medicine). The integrity of PEDF and LRP6 KO was
assessed in conditioned medium and in lysates. Measure-
ment of PEDF levels in culture was performed with by a
commercial enzyme-linked immunosorbent assay kit (Bio-
Products, Frederick, MD).Figure 1. PEDF secretion is regulated by Wnt ligands in an
LRP6-dependent manner. (A) Integrity of the LRP6 small-RNA Analysis and Quantitative Polymerase
Chain Reaction
The RNA was isolated using the RNAEasy mini kit (Qia-
gen). The primer probe sets were obtained from a com-
mercial source (Applied Biosystems, Foster City, CA), and
quantitative reverse-transcription PCR was performed on a
TaqMan ABI 7500 system (Applied Biosystems) as
described elsewhere.13 Target gene expression was
normalized against b-actin.hairpin RNA-mediated knockdown in HepG2 cells was
demonstrated under high (25 mM) and low (1 mM) glucose
conditions. (B) Canonical Wnt3a ligand signiﬁcantly induces
PEDF levels in the presence of the Wnt coreceptor LRP6
(P < .01). Genetic knockdown of LRP6 or its functional
depletion with 1 mM glucose abrogates this effect (not sta-
tistically signiﬁcant). (C) The noncanonical Wnt5a suppresses
PEDF levels when LRP6 is genetically deleted under 25 mM
glucose or reduced by low glucose (P < .01). Experiments
were conducted in duplicate with n ¼ 3–4/group. Data are
presented as mean ± SD.Immunoblotting
Immunoblotting was performed as described else-
where.12 Protein content was determined by Bradford
assay. Lysates (20–30 mg total protein) were separated
under denaturing conditions on a gradient gel (Bio-Rad
Laboratories, Hercules, CA), and transferred to poly-
vinylidene ﬂuoride membranes. After they were blocked in a
5% milk solution, the membranes were incubated overnight
with antibodies. Primary antibodies used were PEDF
from Chemicon (Temecula, CA); transforming growth factor-
b1 (TGF-b1; 3711S), phospho-LRP6 (2568), total LRP6
(2560), nonphosphorylated (active) b-catenin and total b-
catenin, phospho-glycogen synthase kinase-3b (p-GSK3b),
total GSK3b, phospho-extracellular-signal-regulated kinase(p-ERK), total ERK (4370), and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (5174S) from Cell Signaling
Technology (Beverly, MA); collagen I (ab6308) from Abcam
(Cambridge, MA); collagen III (15946) from Novus
538 Protiva et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5Biologicals (Oakville, ON, Canada); and b-actin from Sigma-
Aldrich.
Collagen I blots were run under reducing and nonre-
ducing conditions. After washing in Tris-buffered saline and
0.05% Tween, the primary antibody was labeled using a
peroxidase-conjugated secondary antibody speciﬁc for the
primary antibody species. Samples were resolved on a
gradient gel and transferred to nitrocellulose membranes.
Equivalence of loading was conﬁrmed using b-actin or
GAPDH for lysates, or Coomassie stains for CM. Densitom-
etry was performed using the National Institutes of Health
ImageJ software (http://imagej.nih.gov/ij/).
Hydroxyproline Assays
Hydroxyproline assays were performed using a com-
mercial kit (BioVision Research, Mountain View, CA). Mea-
surements were performed on four separate occasions
using three different sets (n ¼ 3–4/group) of age-matched
PEDF KO and control livers.
Second Harmonic Generation Imaging
Second harmonic generation (SHG) imaging preferen-
tially detects type I, and to a lesser extent type III, ﬁbrillar
collagen.26 Multiphoton stimulation combined with tissue
clearing was used to visualize ﬁbrillar collagen deposition in
volume sections of both WT and KO liver specimens
measuring approximately 5  5  1 mm. Tissue clearing
was performed on formalin-ﬁxed organs using benzyl
alcohol/benzyl benzoate (BABB) in 2:1 ratio as previously
described elsewhere.27 Brieﬂy, tissue specimens were then
dehydrated by graded methanol incubations in 30-minute
intervals and then incubated overnight with BABB. SHG
was measured on a TriM Scope II multiphoton microscope
(LaVision BioTec, Bielefeld, Germany) with 780 nm excita-
tion and 390 nm band pass emission ﬁlter using a 0.95 NA,
25 objective (Leica Microsystems GmbH, Wetzlar, Ger-
many) designed speciﬁcally for BABB immersion. Tissue
volume was determined using intrinsic ﬂuorescence with
960 nm excitation and 600–50 nm band pass ﬁlter detec-
tion. The SHG signal was collected in reﬂection: the spec-
imen was placed on a deep-well slide, and a mirror was
placed underneath to improve collection efﬁciency. The
imaging parameters were kept constant among the speci-
mens, including laser power and scanning speed as well as
detector distance from the specimen. Data were collected in
16-bit depth, and contrast was adjusted using identical in-
tensity thresholds for all images, allowing for direct in-
tensity comparison.
Histology
Immunohistochemical analysis was performed as
described on 14 sequentially obtained human HCC speci-
mens. Sections were deparafﬁnized, treated to inhibit
endogenous peroxidase, and subjected to antigen retrieval.
After incubation with primary antibody, sections were
washed and then incubated with biotinylated anti-mouse
antiserum. Streptavidin complexed with horseradish
peroxidase was added, and labeling was detected usingdiaminobenzidine. Semiquantitative scoring of the immu-
nohistochemical labeling was evaluated by a pathologist
(S.E.C.) using a numerical grading score (1, no staining; 2,
focal positivity; 3, moderate; 4, diffuse, strong immuno-
staining) on 10 nonoverlapping ﬁelds per case with normal
hepatocytes distant to the tumor margin assessed as “Nl
liver.”
Statistical Analysis
The P values were calculated, assuming equal sample
variance, using a two-tailed Student t test on Prism soft-
ware. P < .05 was considered statistically signiﬁcant. Values
were stated as mean ± standard deviation (SD) or standard
error of the mean.
Results
PEDF Secretion Is Wnt3a-Responsive and
Depends on the Wnt Coreceptor LRP6
We evaluated PEDF regulation by Wnt ligands and
dependence upon LRP6. The integrity of the LRP6 KO and
the stimulatory effects of high (25 mM) versus low (1 mM)
glucose on LRP6 and its effector active (nonphosphorylated)
b-catenin were shown (Figure 1A). Canonical Wnt3a (50 ng/
mL) led to a greater than twofold increase in PEDF levels
that was LRP6 dependent (Figure 1B, P < .01). In the
absence of the LRP6, Wnt3a had no effect on PEDF levels.
Similarly, Wnt3a had no effect on PEDF levels under 1 mM
glucose conditions, likely reﬂecting markedly suppressed
LRP6 levels seen in this condition. Thus, Wnt3a-stimulated
induction of PEDF levels are LRP6 dependent.
The noncanonical Wnt pathway includes the Wnt5a
ligand and its orphan receptor, ROR2 (receptor tyrosine
kinase-like orphan receptor 2), and counters the effects of
the canonical pathway.28 To determine whether PEDF could
be modulated by the noncanonical pathway, Wnt5a was
added to HepG2 cells with and without LRP6. Wnt5a did not
alter PEDF levels under high-glucose conditions in the
presence of the LRP6 receptor. When the canonical receptor
LRP6 was deleted, Wnt5a signiﬁcantly suppressed PEDF
protein levels (Figure 1C, P < .01). Thus, deletion of LRP6
favors the noncanonical pathway and lowers PEDF under
high-glucose conditions.
Similarly, the 1 mM glucose condition leads to a func-
tional depletion of the LRP6 receptor (Figure 1A) without
genetic manipulation. Here, the Wnt5a ligand signiﬁcantly
decreased PEDF under scrambled and LRP6 KO conditions
indicating that the noncanonical Wnt ligands can decrease
PEDF in the setting of diminished LRP6 levels (Figure 1C, P
< .01 for low glucose with and without LRP6). Thus, ca-
nonical Wnt3a and the noncanonical Wnt5a differentially
regulate PEDF levels.
PEDF Knockout Livers Resemble Experimental
and Human Hepatocellular Carcinoma Marked by
Wnt/b-Catenin Signaling
To explore PEDF’s role in the liver, gene expression
proﬁling was done in KO versus WT livers. There were 1113
Table 1.Top 10 Enriched Chemical and Genetic Perturbation Gene Sets Corresponding to PEDF Null Livers
Gene Set Name FDR q Valuea Gene Set Description
LEE_LIVER_CANCER_ACOX1_UP <.001 Genes up-regulated in HCC of ACOX1 knockout mice
LEE_LIVER_CANCER_E2F1_UP <.001 Genes up-regulated in HCC induced by overexpression of E2F1
LEE_LIVER_CANCER_MYC_E2F1_UP <.001 Genes up-regulated in HCC from MYC and E2F1 double transgenic
mice
LEE_LIVER_CANCER_MYC_TGFA_UP <.001 Genes up-regulated in HCC tissue of MYC and TGFA double
transgenic mice
ICHIBA_GRAFT_VERSUS_HOST_
DISEASE_35D_UP
<.001 Hepatic graft versus host disease day 35: genes up-regulated in
allogeneic vs syngeneic bone marrow transplant
KHETCHOUMIAN_TRIM24_TARGETS_UP <.001 Retinoic acid-responsive genes up-regulated in HCC samples of
TRIM24 knockout mice
LEE_LIVER_CANCER_CIPROFIBRATE_UP <.001 Genes up-regulated in HCC induced by ciproﬁbrate
LEE_LIVER_CANCER_DENA_UP <.001 Genes up-regulated in HCC induced by diethylnitrosamine
WIELAND_UP_BY_HBV_INFECTION <.001 Genes induced in the liver during hepatitis B viral clearance in
chimpanzees
BORLAK_LIVER_CANCER_EGF_UP <.001 Genes up-regulated in HCC developed by transgenic mice
overexpressing a secreted form of epidermal growth factor in liver
Note: Gene set enrichment analysis showed that expression signatures in PEDF knockout mouse livers resembled those
found in genetic and chemical models of HCC. Of the top 10 enriched chemical and genetic perturbation gene sets, eight
represented rodent models of HCC, and two (Ichiba and Wieland) sets are related to inﬂammatory liver conditions. HCC,
hepatocellular carcinoma.
aFDR (false-discovery rate): adjusted P value (FDR q value).
September 2015 PEDF and Wnt Signaling in the Liver 539gene entities differentially expressed between WT and KO
animals at FDR  .05 and 1.3-fold expression cutoffs. Out of
1113 genes 344 were up-regulated in KOs, and 769 were
down-regulated (Supplementary Table 1). Grouping these
genes by GO categories using hypergeometric modelTable 2.Up-Regulated Gene Sets From PEDF KO Livers Match
Wnt/b-Catenin Signaling
Name FDRa
HOSHIDA LIVER CANCER
SUBCLASS S1
<.001 Gene signature from
http://www.broadin
SUBCLASS_S1
PUBMED ID: 19723
KENNY CTNNB1 TARGETS UP .002 Genes up-regulated
catenin gene
http://www.broadin
PUBMED ID: 15642
CAVARD LIVER CANCER
MALIGNANT VS BENIGN
.003 Genes identiﬁed by
malignant and b
adenoma with a
http://www.broadin
MALIGNANT_VS
PUBMED ID: 16314
CHIANG LIVER CANCER
SUBCLASS CTNNB1 UP
.031 Genes up-regulated
(CTNNB1) gene
http://www.broadin
SUBCLASS_CT
PUBMED ID: 18701
CAIRO HEPATOBLASTOMA UP .050 Gene signature from
http://www.broadin
PUBMED ID: 19061
aFDR (false-discovery rate): adjusted P value (FDR q value).showed that most up-regulated GO categories were related
to extracellular matrix function, lipid metabolism, immune
response, DNA replication, phase I and II enzymes (FDR 
.05). Most down-regulated GO categories were related to
ribosomal and mitochondrial function and numerousing Gene Expression Signatures Associated With Aberrant
Description, Web Link, and PubMed ID
HCC subset with aberrant Wnt activation
stitute.org/gsea/msigdb/cards/HOSHIDA_LIVER_CANCER_
656
in mammary epithelial cells with constitutively active mutant b-
stitute.org/gsea/msigdb/cards/KENNY_CTNNB1_TARGETS_UP.html
117
subtractive hybridization to compare gene expression between
enign components of a human HCC occurring from pre-existing
ctivated b-catenin
stitute.org/gsea/msigdb/cards/CAVARD_LIVER_CANCER_
_BENIGN.html
847
in the subclass of HCC characterized by activated b-catenin
stitute.org/gsea/msigdb/cards/CHIANG_LIVER_CANCER_
NNB1_UP.html
503
human hepatoblastoma characterized by Wnt/b-catenin activation
stitute.org/gsea/msigdb/cards/CAIRO_HEPATOBLASTOMA_UP.html
838
Figure 2. Expression proﬁling of PEDF knockout (KO) livers demonstrates up-regulation of genes involved in Wnt/b-
catenin signaling. Items in red represent genes that were up-regulated <1.1-fold in PEDF KO compared with wild-type (WT)
livers. In particular, Frizzled ligands known to play a role in hepatocarcinogenesis were up-regulated. Induction of multiple
downstream targets of Wnt/b-catenin (Ccnd1, Ccnd3, Jun, and Plau) suggests transcriptional activation of Wnt/b-catenin
signaling.
540 Protiva et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5primary metabolic processes such as nitrogen compound
metabolism, glutamine family amino acid metabolic process,
urea cycle, and carboxylic acid metabolism, and peptidase
inhibitory activity (FDR < .05).To further characterize the gene expression changes in
KO mice, GSEA using curated pathways as well as GO
categories were performed. Consistent with analysis by
moderated t test, the GSEA showed that most up-regulated
Figure 3. PEDF inhibits LRP6 phosphorylation in murine livers. (A) Increased phospho-LRP6 and nonphosphorylated
(active) b-catenin in 7-month-old PEDF knockout (KO) mice and corresponding quantiﬁcation of immunoblots (P < .02). (B)
Younger 2 month-old) PEDF KO mice also show increased phosphorylation of LRP6 (P < .05). (C) PEDF restoration in vivo
reduces LRP6 activation (P ¼ .05). (D) Gene expression of Ccnd1 and c-Jun in murine control and PEDF KO livers. Repre-
sentative data from duplicate experiments conducted with n ¼ 3–4/group for immunoblots. Quantitative reverse-transcription
polymerase chain reaction data, n ¼ 6/group. Data are presented as mean ± SD.
September 2015 PEDF and Wnt Signaling in the Liver 541pathways were related to cell proliferation, inﬂammatory
responses, collagen expression, extracellular matrix func-
tion, and phase I and phase II enzymatic activity
(Supplementary Table 2). Subsequently, another GSEA was
performed to test for similarities between gene expressionproﬁles in PEDF KO mouse livers and curated gene sets
representing expression signatures of genetic and chemi-
cal perturbation. This analysis showed that the most
signiﬁcantly enriched gene sets represented rodent
models and human samples of HCC tissues and various
542 Protiva et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5inﬂammatory liver conditions, suggesting that loss of PEDF
leads to gene expression changes similar to those found in
HCC (Table 1, Supplementary Table 3). In fact, eight out of
top 10 enriched gene sets represented rodent models of
HCC (Table 1).PEDF Knockout Livers Display a Genomic
Signature Resembling Hepatocellular Carcinoma
Categorized by Wnt/b-Catenin Signaling
Comparison of liver-speciﬁc gene expression signatures
of genetic and chemical perturbation to PEDF KO livers
September 2015 PEDF and Wnt Signaling in the Liver 543showed a striking resemblance to various human HCC
subsets marked by overactive Wnt/b-catenin signaling
(Table 2).3,29–31 Furthermore, PEDF KO liver expression
proﬁles also correlated with the gene expression patterns of
nonliver tissue experimental models where constitutively
active mutant b-catenin was overexpressed (Table 2).32
Additionally, we observed overexpression of both Fzd 1
and 7, Wnt coreceptors that have been reported to be
induced in human HCC specimens and cell lines (Figure 2).33
Downstream targets of Wnt/b-catenin signaling, such as
Ccnd1, Ccnd3, and c-Jun, were also found to be up-regulated
in PEDF KO livers.
PEDF Inhibits Activation of the Wnt Coreceptor
LRP6 In Vivo
To evaluate concordance with the genomic analysis, we
interrogated components of the Wnt/b-catenin signaling
pathway in PEDF KO livers before and after PEDF recon-
stitution. PEDF KO livers showed enhanced phospho-LRP6
levels and active b-catenin compared with WT controls in
7-month-old mice (Figure 3A, P < .02). A similar activation
of LRP6 was seen in 2-month-old mice (Figure 3B, P < .05).
Restoration of PEDF in KO mice resulted in decreased LRP6
phosphorylation without affecting total LRP6 levels
(Figure 3C, P ¼ .05). Moreover, gene expression of down-
stream canonical Wnt signaling pathway targets Ccnd1 and
c-Jun was increased in PEDF KO livers versus controls
(Figure 3D, P < .05). These results indicate that PEDF
functions as an antagonist of hepatic LRP6 activation in vivo
and that exogenous PEDF can inhibit LRP6 activation
in vivo.
PEDF Loss Is Associated With Increased
Fibrogenic Markers and Enhanced Cellular
Proliferation
PEDF expression is reduced in human cirrhosis, and its
restoration in two different models of experimental liver
cirrhosis mitigates ﬁbrotic changes.14,16 Consistent with this
ﬁnding, the GSEA revealed an induction of pathways related
to extracellular matrix deposition in PEDF KO liver tissue
(Figure 4A, Supplementary Table 1). Biochemical assess-
ment of collagen content and speciﬁc collagen subtypes,
however, revealed a more complex picture of the matricel-
lular changes in the absence of PEDF.
Conﬁrmation of ﬁbrogenic cytokines with quantitative
PCR showed that tgfb1 and pdgfa were signiﬁcantlyFigure 4. (See previous page). Absence of PEDF is permissiv
heat maps show up-regulation of DNA replication, collagen,
represent graphic gene expressions of the genes contributing
enrichment analysis (core enriched genes). The log transformed
(B) PEDF KO livers demonstrate enhanced expression of proﬁbr
and ﬁbrillar collagen. (C) Decreased hydroxyproline in PEDF
demonstrates enhanced ﬁbrillar collagen deposition adjacent to
(TGF-b) and ﬁbrillar type I and III collagens were increased in
Quantitative reverse-transcription polymerase chain reaction d
Representative SHG images taken from n ¼ 3/group. Represen
from three different sets of age-matched livers; data are presen
from three separate experiments; data are presented as meanincreased, and thbs1, an activator of transforming growth
factor-b, showed a trend toward increased expression
(Figure 4B). Angiogenic factors play a role in promoting
ﬁbrogenesis and can be regulated by Wnt pathway activa-
tion.34 Enhanced expression of vegfa was present in PEDF
KO livers (Figure 4B). Similarly, expression of col1a was
increased but not that of other ﬁbrillar collagen types such
as col5a1. Surprisingly, the total hydroxyproline content of
PEDF KO livers was 75% of the control livers (Figure 4C),
indicating that overall the collagen content was decreased.
However, SHG imaging revealed visual evidence of increased
ﬁbrillar collagen in PEDF KO livers (Figure 4D). Consistent
with the SHG imaging, the ﬁbrillar collagen types I and III
levels in PEDF KO livers were higher than in the controls
(Figure 4E). Thus, a preferential induction of ﬁbrillar
collagen occurs in PEDF KO livers, but it is accompanied by
an overall decrease in other collagen or structural proteins
that contain hydroxyproline residues.
PEDF Is a Secreted Antagonist of Wnt/b-Catenin
Signaling in Hepatocellular Carcinoma Cells
Findings in murine livers were extended to human HCC
cells to determine whether PEDF functions as a Wnt
antagonist. Both HepG2 and Huh7 cells secreted PEDF into
the CM (Figure 5A and C). In HepG2 cells, siRNA-mediated
PEDF knockdown led to increased phospho-LRP6 and
active b-catenin levels (Figure 5A and B, P < .01). Similar
results were observed in Huh-7 cells after PEDF knockdown
(Figure 5C and D, P < .01).
A 34-mer sequence within PEDF mediates its well-
documented antiangiogenic effects.25 Because angiogenesis
requires Wnt signaling, we surmised that the PEDF 34-mer
is responsible for its effects on Wnt/b-catenin signaling.
Adding the PEDF 34-mer decreased the levels of active
phospho-LRP6 and active b-catenin (Figure 5E, P < .01).
Downstream regulators and targets of Wnt signaling such as
GSK3b and phospho-ERK levels corresponded to the effects
of Wnt blockade with PEDF 34-mer (Figure 5F). Levels of
phospho-GSK3b (inactive form) were diminished consistent
with increased intracellular active GSK3b and enhanced
degradation of b-catenin seen with Wnt blockade. The
downstream targets of b-catenin such as phospho-ERK were
decreased. Moreover, transcriptional targets of canonical
Wnt signaling such as ccnd1 and c-Jun were suppressed with
the 34-mer (Figure 5G). These results demonstrate that
PEDF antagonizes Wnt/b-catenin signaling in human HCCe for induction of ﬁbrogenic markers. (A) Gene expression
and extracellular matrix organization pathways. Heat maps
most to statistically signiﬁcant enrichment score in gene set
color expression scale is shown at the bottom of the ﬁgure.
otic cytokines (tgfb1, P < .05; pdgfa, P < .01, vegfa, P < .01)
KO livers. (D) Second harmonic generation (SHG) imaging
vessels in PEDF KO livers. (E) Transforming growth factor-b
PEDF KO livers under reducing and nonreducing conditions.
ata, n ¼ 5–6/group; data are presented as mean ± S.E.M.
tative hydroxyproline data from n ¼ 4 separate experiments
ted as mean ± SD. Immunoblots are from n ¼ 3 livers/group
± SD.
Figure 5. PEDF inhibits canonical Wnt/b-catenin signaling in human hepatocellular carcinoma (HCC) cells. (A) PEDF
knockdown in HepG2 cells results in increased LRP6 phosphorylation and increased active b-catenin. (B) Corresponding
quantiﬁcation of phospho-LRP6 and active b-catenin after RNA interference of PEDF in HepG2 cells (P < .01). (C) Huh-7 cells
display increased LRP6 phosphorylation and active b-catenin after depletion of endogenous PEDF. (D) Quantiﬁcation of
phospho-LRP6 and active b-catenin after RNA interference of PEDF in Huh-7 cells (P < .01). (E) A PEDF 34-mer peptide
decreased LRP6 phosphorylation and active b-catenin levels in Huh-7 cells (P < .01). (F) Changes in the levels of downstream
targets of canonical Wnt signaling such as phospho-GSK3b/total GSK3b and phospho-ERK/total ERK reﬂect inhibition of Wnt
signaling with the PEDF 34-mer. (G) Gene targets of the Wnt pathway, ccnd1 and c-Jun, were signiﬁcantly suppressed with
PEDF 34-mer (P < .05 and P < .01, respectively). Representative data are shown from three separate experiments conducted
with n ¼ 3/group for siRNA experiments. Data from 34-mer peptide experiments were performed in duplicate and n ¼ 3/group.
Data are presented as mean ± SD.
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Figure 5. (continued).
September 2015 PEDF and Wnt Signaling in the Liver 545cells and point to a 34-amino-acid peptide fragment derived
from PEDF that mediates LRP6 blockade.Induction of Liver Fibrosis and Sporadic
Hepatocellular Carcinoma in PEDF Knockout
Mice After Western Diet Feeding
Genomic proﬁling of PEDF KO livers corresponded to
various human HCC subsets marked by overactive Wnt/b-
catenin, but spontaneous HCC did not develop in PEDF KO
mice up to 1 year of age (data not shown). To test whether
diet-induced obesity could induce HCC formation in the
absence of PEDF, a Western diet (40% fat, 44% carbohy-
drate, 16% protein) was given to PEDF KO and WT mice for
6 to 8 months. A Western diet increased ﬁbrosis in WT and
PEDF KO mice as shown by trichrome staining and hy-
droxyproline measurements (Figure 6A).
Increased ﬁbrillar collagen deposition as seen with SHG
imaging was more apparent in PEDF KO than WT livers(Figure 6B). Three-dimensional reconstructed images from
SHG imaging revealed an increase in ﬁbrillar collagen adja-
cent to vessels, outlining their structures (Figure 6B). A
subset of PEDF KO mice (3 of 12) developed macroscopic
tumor formation compared with none (0 of 12) in the control
mice (Figure 6C) after chronic Western diet feeding. Histo-
logic examination showed features consistent with a well-
differentiated HCC with the increased presence of unpaired
blood vessels (Figure 6C, arrows). In contrast to the diet-
induced HCC, a one-time diethylnitrosamine injection did
not result in HCC formation in either the WT or KO mice at 6
months (data not shown). Thus, PEDF deﬁciency combined
with a chronic Western diet led to sporadic HCC formation.PEDF Expression Is Reduced in Human
Hepatocellular Carcinoma Specimens
A previous study of embryonic and adult human tissue
sites demonstrated that the liver has the highest
Figure 6. A Western diet induces liver ﬁbrosis and sporadic hepatocellular carcinoma (HCC) in PEDF knockout (KO)
mice. (A) Six months of Western diet feeding induced liver ﬁbrosis in wild-type (WT) and PEDF KO mice as demonstrated by
trichrome staining (magniﬁcation 20; size bars: 100 mM) and measured by hydroxyproline content. (B) Second harmonic
generation (SHG) imaging shows increased ﬁbrillar type I/III collagen deposition in PEDF KO mice livers (bottom panels)
compared with WT (top panels) mice fed a Western diet. Magniﬁcation: left 4; right 20. Three-dimensional reconstruction of
serial SHG images reveals prominence of ﬁbrillar collagen around blood vessels in PEDF KO livers. (C) PEDF KO mice showing
macroscopic tumor in mice fed the Western diet versus control diet. Bottom panel shows histology of a well-differentiated
HCC arising in KO mouse fed a Western diet. L, liver; T, tumor; magniﬁcation 10, arrow at demarcation between liver and
HCC; 20, arrows highlighting unpaired blood vessels in HCC.
546 Protiva et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5expression levels of the PEDF gene, and the recent tissue-
based map of the human proteome conﬁrmed this
ﬁnding.20,21 Relative to the high endogenous levels in the
normal liver, we asked whether PEDF levels in HCC
specimens were diminished. Staining of PEDF showed
diffuse and strong immunoreactivity for PEDF in normal
liver tissue (Figure 7A, left). In contrast, PEDF immuno-
labeling was statistically signiﬁcantly reduced in HCC
compared with the adjacent liver (Figure 7A, middle andright, and B; P < .01). Thus, human HCC specimens
demonstrated decreased PEDF expression compared with
the adjacent nontransformed hepatocytes.Discussion
Aberrant Wnt/b-catenin signaling underlies a number of
malignancies, including HCC.3,35 Our study has identiﬁed
PEDF as an endogenous inhibitor of LRP6 activation that is
Figure 7. PEDF expression is reduced in human hepatocellular carcinoma (HCC). (A) Immunostaining for PEDF in human
livers (top) and human HCC specimens (bottom). (B) Semiquantitative scoring of PEDF staining demonstrates increased la-
beling in normal liver compared with HCC specimens (P < .01; n ¼ 14). NL, normal.
September 2015 PEDF and Wnt Signaling in the Liver 547secreted in response to canonical Wnt ligands. Enhanced
LRP6 and b-catenin activation was seen in the livers of PEDF
KO mice and in two human HCC cell lines where PEDF was
depleted. Further, adding a PEDF 34-mer inhibited LRP6,
active b-catenin, and downstream targets of Wnt signaling,
thereby identifying the region on PEDF that mediates Wnt
inhibitory effects. These data support the idea that PEDF
functions as a part of a negative feedback loop to modulate
Wnt signaling. Gene enrichment data supported this inter-
action. Further, biochemical analyses of PEDF KO murine
livers before and after PEDF reconstitution in vivo conﬁrmed
that PEDF can block Wnt signaling in the liver. PEDF knock-
down in two human HCC cell lines led to increased Wnt/b-
catenin signal transduction with a speciﬁc 34-amino-acid
region mediating these effects. Thus, PEDF is regulated by
and inhibits the canonical Wnt/b-catenin pathway in the
murine liver and in two human HCC cell lines.
The genomic analysis in this study correlated with ge-
netic proﬁles of murine hepatocarcinogenesis and human
HCC subsets marked by overactive Wnt/b-catenin signaling,
but PEDF deﬁciency alone did not result in HCC formation. A
prolonged nutritional challenge induced only a fraction of
animals to develop a well-differentiated HCC. These results
are consistent with models of hepatic overexpression ofnormal and mutant b-catenin that do not result in sponta-
neous HCC.35 Paradoxically, deletion of b-catenin from the
liver is permissive for HCC formation after injection with
diethylnitrosamine.36 This surprising effect of b-catenin
deletion conferring an increased rate of HCC development in
murine models, rather than its overexpression, reﬂects the
importance of this pathway for liver tissue homeostasis. In
its absence, the liver is prone to injury from oxidative stress
and enhanced ﬁbrosis.36 Thus, ﬁndings from b-catenin
transgenic mice are at odds with those from genomic and
immunohistochemical studies in human HCC, which point to
Wnt/b-catenin signaling as a signiﬁcant driver in a subset of
HCC.3 The absence of HCC found in transgenic models of b-
catenin overexpression and the occurrence of HCC with b-
catenin deletion highlights the limitations of constitutively
active or deletion of b-catenin, where temporal and context-
speciﬁc activity of b-catenin may more accurately capture
its role in human disease.
Absence of PEDF led to complex changes to the ECM
of the liver. Despite lower total hydroxyproline levels, type
I/III collagen content and SHG imaging demonstrated
increased deposition of ﬁbrillar collagen in PEDF KO livers.
In experimental and human cirrhosis specimens, PEDF
levels are also depleted.14 Restoration of PEDF in
548 Protiva et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5experimental models of CCl4 [chemokine (C-C motif) ligand
4] and bile-duct ligated cirrhosis ameliorates tissue ﬁbrosis,
suggesting an important role for endogenous PEDF in
maintaining quiescence of the liver ECM.14,16 These ﬁndings
are consistent with studies that demonstrate Wnt/b-catenin
signaling as a regulator of the ﬁbrotic response in diverse
organs.37–39 Further, examination of the PEDF null state in
humans, osteogenesis imperfecta type VI, points to abnor-
malities in the extracellular matrix.24,40 These ﬁndings
suggest that PEDF may regulate matricellular content in
multiple organ sites.
This study provides further evidence to support the role
of PEDF in Wnt/b-catenin signaling. The discovery through
exome sequencing that null mutations in PEDF cause
osteogenesis imperfecta type VI implicated PEDF’s role in
modulating Wnt/b-catenin signaling in human dis-
ease.22,40,41 We and others have shown that PEDF could
induce differentiation of progenitor cells and that these ef-
fects were LRP6 dependent.22,42 In the eye, PEDF inhibited
Wnt3a-mediated b-catenin nuclear translocation, and recent
studies showed that PEDF directly suppressed other Wnt
modulators such as sclerostin.19,41 Exogenous PEDF protein
and a peptide derived from PEDF demonstrate inhibitory
effects on Wnt signaling in the liver and in two HCC cell
lines, thereby pointing to its role in attenuating Wnt
signaling in a negative feedback loop.
Interestingly, PEDF appears to promote Wnt/b-catenin
signaling in stem cell populations but inhibits Wnt signaling
in differentiated cells.22,41 Differential effects are also seen
in Wnt ligands and Wnt-related proteins such as Wnt5a and
Dickkopf2, and stem from selective expression patterns of
Wnt coreceptors.28,43,44 Future studies detailing the
expression patterns of different Fzd species should allow
identiﬁcation of the receptor combination that directs
PEDF’s different functional outcomes as they pertain to Wnt
signaling.
In summary, PEDF functions as an endogenous inhibitor
of Wnt/b-catenin signaling in the liver and in human HCC
cells. These ﬁndings provide a framework for understanding
the antitumor properties of PEDF in other cancer types.References
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Supplementary Table 1.List of Statistically Signiﬁcant
Differentially Expressed Gene
Entities in PEDF Knockout Animals
Versus Wild-Type (FDR < .05 and
Expression Cutoff of 1.3-Fold)
Symbol Fold Up Symbol Fold Down
Cyp2b9 6.730 Serpinf1 (KO GENE) 143.796
Gsta1 4.853 Serpina1e 8.049
Cyp2b23 4.285 Hsd3b5 5.549
Ly6d 4.166 Lpin1 3.815
Gsta2 3.822 Serpina4-ps1 3.642
Tubb2b 3.390 Nnmt 3.193
Lcn2 3.346 Nnmt 3.105
Anxa2 2.943 Egfr 3.080
Mod1 2.733 C6 3.023
Cidec 2.654 Egfr 2.957
S100a11 2.579 Aatk 2.871
Bcl6 2.524 C8b 2.749
Orm2 2.467 Egfr 2.578
Wfdc2 2.254 C6 2.577
Aqp8 2.222 Cyp7b1 2.553
Insig2 2.192 Cyp4a12b 2.465
Tceal8 2.169 Clca3 2.437
Lgals3 2.167 Sds 2.380
Spon2 2.165 Slc38a2 2.378
Aqp8 2.127 Ela1 2.333
Ubd 2.079 2200001I15Rik 2.305
H2-Ab1 2.062 Cyp7a1 2.302
Apoa4 2.056 Fbxo31 2.246
Cbr3 2.053 EG13909 2.223
Hsd17b6 1.980 Selenbp2 2.181
Lpl 1.978 Socs2 2.177
Cd74 1.972 Upp2 2.167
Raet1b 1.967 Fbxo31 2.165
Egr1 1.965 Tsc22d3 2.161
Pdk4 1.927 C8a 2.142
Ttc39a 1.900 Cyp4f14 2.136
Slc17a4 1.878 2810439F02Rik 2.120
Gstm2 1.850 Slc29a1 2.110
Sqle 1.829 F11 2.106
Spp1 1.793 Siat9 2.095
Ccnd1 1.788 Mup4 2.095
H2-Aa 1.786 LOC100047762 2.070
Sepp1 1.785 Cish 2.065
H2-Ab1 1.780 Ptpre 2.059
Insig2 1.735 Por 2.055
Cd74 1.734 Ccrn4l 2.022
Insig2 1.734 Hpd 2.013
Aqp4 1.724 Upp2 1.984
Vldlr 1.724 Prei4 1.980
Srxn1 1.722 F11 1.978
Elovl6 1.711 Prodh 1.961
Slpi 1.707 Zap70 1.960
Supplementary Table 1.Continued
Symbol Fold Up Symbol Fold Down
Lgals1 1.706 Por 1.960
Gdf15 1.696 Zxda 1.954
Ptp4a2 1.690 Gne 1.950
LOC100047046 1.689 Kcnk5 1.918
LOC641240 1.684 Pptc7 1.906
Limk1 1.683 Eif4ebp3 1.894
Ntrk2 1.680 2810439F02Rik 1.890
H2-Ab1 1.679 Tk1 1.879
Gstm2 1.679 Zap70 1.875
Fam129b 1.676 Tef 1.871
Col6a1 1.673 Angptl4 1.851
Ctps 1.672 Chac1 1.838
Nudt18 1.669 Gm129 1.836
Anxa5 1.668 Agxt 1.835
Zfp36l1 1.664 Lpin2 1.835
Ankrd56 1.658 EG13909 1.834
H2-Eb1 1.652 Asl 1.824
S100a10 1.648 Afmid 1.821
Ccnd1 1.642 Tle1 1.820
Srxn1 1.641 Afmid 1.820
Lyzs 1.639 Spata2L 1.817
Cd63 1.637 Upp2 1.814
Idh2 1.634 St3gal5 1.802
Uhrf1 1.633 Chka 1.802
Uap1l1 1.632 rp9 1.797
Dusp6 1.625 Smarcd2 1.796
Aldh1a1 1.623 Gpt1 1.792
Mfge8 1.619 Cyp4f13 1.784
Acnat2 1.614 Nrbp2 1.784
Cxcl9 1.614 Cps1 1.778
Acly 1.609 Cebpb 1.773
Tsc22d1 1.609 Serpinf2 1.762
Rtn4rl1 1.597 Hs6st1 1.757
Plekha1 1.596 Gls2 1.750
Cyp4a14 1.595 Susd4 1.750
Usp18 1.594 Apom 1.744
Cd9 1.591 Klhl21 1.744
Smpd3 1.591 Fkbp5 1.743
Hist1h2ao 1.590 Prhoxnb 1.743
Col4a1 1.587 Cbs 1.741
Lypla1 1.583 Lgals4 1.732
Gstm2 1.583 Ccbl1 1.727
Rcan1 1.582 Upp2 1.726
Tlr2 1.571 Foxa3 1.724
Prune 1.569 Sardh 1.711
LOC100043671 1.567 Clec2d 1.710
Lgals3bp 1.567 B230342M21Rik 1.708
Ccbl2 1.567 Afmid 1.708
Hrsp12 1.566 Bach1 1.708
Elovl5 1.562 Tmem50a 1.707
549.e1 Protiva et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5
Supplementary Table 1.Continued
Symbol Fold Up Symbol Fold Down
Ccnd1 1.560 Mlxipl 1.706
Gadd45a 1.559 Gcgr 1.703
Samd9l 1.556 Agpat6 1.697
Gas6 1.555 Cyp4f15 1.693
Esd 1.549 Plg 1.692
Cyp3a11 1.548 Cyp1a2 1.687
Sparc 1.547 Serpina3k 1.676
LOC100047934 1.542 D4Bwg0951e 1.675
Ctsa 1.538 Nﬁc 1.673
Ppic 1.536 Hhex 1.671
Nipsnap3a 1.536 Ush2a 1.670
Mcm6 1.533 Ang 1.668
Axl 1.531 Hyal1 1.666
Tmem43 1.530 Pgls 1.663
Plscr1 1.528 Itih3 1.662
Lum 1.526 Rnase4 1.659
2410004L22Rik 1.526 Ttc36 1.655
Cdkn1a 1.523 1700019G17Rik 1.651
Arl8a 1.521 Cps1 1.650
Acot4 1.519 Rps5 1.646
Laptm5 1.515 9530058B02Rik 1.643
St5 1.515 2310076L09Rik 1.642
Gbp2 1.515 Il6ra 1.638
Sirpa 1.513 Mbd1 1.638
Iﬁ27 1.512 Atp5sl 1.635
Sqle 1.511 Kcnk5 1.635
Acot3 1.509 Gnat1 1.634
Spc25 1.505 Abcg8 1.629
B930041F14Rik 1.504 Tmem160 1.622
Tgfbr2 1.502 Hist1h2bm 1.621
Tgm2 1.502 Hes6 1.619
Cbr3 1.500 Asl 1.618
Aldh1a7 1.500 Acaa2 1.617
Hprt1 1.497 Zfp259 1.617
Entpd5 1.497 Klf13 1.612
Cyba 1.497 Hist2h2aa1 1.607
Tpm1 1.496 Ccbl1 1.593
Acox1 1.495 Npr2 1.593
Cyp4a31 1.493 Map1lc3a 1.592
Atp5a1 1.492 Ephx2 1.590
Col6a1 1.489 Tmem183a 1.587
Dusp6 1.488 Scnn1a 1.586
Tmem77 1.486 Afmid 1.586
Fos 1.483 Igfals 1.582
LOC100048346 1.483 Fgf1 1.582
Iﬁt3 1.482 Cnpy2 1.582
Ctsc 1.480 0610012D14Rik 1.582
Serpina7 1.480 Tspan31 1.581
Pex11a 1.478 Rbm5 1.580
Ccdc80 1.475 Ugt2b1 1.580
Supplementary Table 1.Continued
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Rnf125 1.475 Med25 1.578
Tm4sf4 1.475 Eif4ebp1 1.578
St5 1.474 Serpina11 1.577
Col5a1 1.474 Ass1 1.577
Cyp2a5 1.474 Nfkbia 1.574
Enc1 1.473 Lcat 1.573
Plscr1 1.472 Rps10 1.572
Aldh1b1 1.470 Atad3a 1.571
Lamb3 1.469 Hist1h2bn 1.570
Cdc20 1.468 Upb1 1.568
Cxcl10 1.468 Cpsf4l 1.563
H2-DMb1 1.467 Fn3k 1.563
Vps29 1.466 Klf9 1.561
Igf2bp2 1.466 Ivd 1.558
Csf1r 1.464 Prodh2 1.558
Ear2 1.463 Mcm10 1.558
Cyp2c29 1.460 Mrpl55 1.557
Dsp 1.460 Prodh2 1.556
Tubb6 1.459 Sri 1.555
Ctsc 1.459 Eef2 1.552
Tnfrsf22 1.458 Pla1a 1.551
Gadd45a 1.458 Cisd1 1.551
Mmp2 1.453 Serpinf2 1.549
Gstm1 1.451 P2ry1 1.547
Cd52 1.448 4933426M11Rik 1.547
Vldlr 1.445 Alas1 1.546
Aadac 1.444 Dedd2 1.540
Glul 1.444 Pipox 1.536
Bcap31 1.443 Fam152b 1.535
Ly6a 1.442 1300017J02Rik 1.530
Abcb11 1.441 Abcc6 1.529
Loxl1 1.441 Sema4g 1.529
Col4a2 1.436 BC031353 1.529
Mvd 1.436 Brap 1.528
Il1b 1.434 Lsm4 1.527
Mcm4 1.433 Slc38a3 1.527
Slc13a3 1.432 Pex6 1.526
Net1 1.432 Nﬁx 1.521
Hist1h2ak 1.430 Als2 1.520
Ugt2b35 1.430 Errﬁ1 1.519
Apoc2 1.428 Ldb1 1.518
Mcm5 1.426 Hc 1.516
Rnd2 1.426 Ptms 1.516
Gclc 1.426 Agt 1.516
Pparg 1.425 Igf1 1.515
Gpam 1.425 Akr7a5 1.515
Osbpl3 1.425 Ddx6 1.513
Slc41a2 1.422 Hpn 1.513
Tnfaip2 1.422 Stard10 1.513
Tmsb4x 1.421 Mafg 1.511
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Mcm6 1.420 Tsku 1.510
Khk 1.417 Cyp2c37 1.508
Fam110a 1.416 Rpl34 1.508
Mme 1.416 Rbm4b 1.507
LOC677317 1.415 Bmp1 1.506
4931406C07Rik 1.414 Wdr45l 1.506
Klf6 1.412 Afmid 1.505
Ywhah 1.411 Ppp1r10 1.505
LOC100047963 1.409 Afmid 1.504
Nampt 1.409 Pop5 1.504
Hist1h2af 1.408 4833421E05Rik 1.502
Emr1 1.406 OTTMUSG00000000231 1.502
Dapk2 1.405 Pscd1 1.500
S100a8 1.404 Vgll4 1.499
Hprt1 1.403 F7 1.499
1810023F06Rik 1.401 Tmem42 1.499
Ndufa5 1.401 Gm129 1.497
Bmp4 1.399 Saps3 1.496
Akr1c14 1.397 Cyp2c67 1.496
Cyp2c39 1.395 Oat 1.495
Vldlr 1.395 1110001J03Rik 1.494
Nqo1 1.394 Glyctk 1.494
Jun 1.394 Srrm2 1.492
LOC100048733 1.394 Tst 1.492
Tm4sf4 1.393 Sdsl 1.492
Rtn4 1.391 Fgg 1.491
Iqgap1 1.391 Hist1h2bk 1.490
Arhgdib 1.391 Klf1 1.490
Rcan2 1.389 F2 1.490
Palmd 1.388 Elovl3 1.487
Hist1h2an 1.387 Ctdsp2 1.485
Rcan2 1.386 Cbs 1.485
Tmem49 1.385 Ppm1k 1.483
Entpd5 1.384 Cyp1a2 1.483
Idi1 1.382 Hsp105 1.482
Nsdhl 1.381 1110032A13Rik 1.481
Slamf9 1.381 H2afy 1.480
Trim2 1.380 Dnajb6 1.480
Lip1 1.377 Keg1 1.480
6330409N04Rik 1.376 Slc35b2 1.480
9030625A04Rik 1.376 Tmem19 1.479
Cxadr 1.376 Fam125a 1.478
Pltp 1.375 Gde1 1.478
Agpat9 1.375 Gpr182 1.477
Zfp608 1.375 D9Wsu20e 1.477
Gale 1.375 Gpr108 1.475
Rasl11b 1.374 Rps8 1.475
Tpm4 1.374 Lman1 1.475
Saa2 1.374 Rpl23 1.474
BC005537 1.372 Zfp91-cntf 1.474
Supplementary Table 1.Continued
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Mcm2 1.372 Upf1 1.473
Lhfp 1.370 F10 1.473
Slc23a2 1.369 Acot1 1.472
Usp18 1.368 Slc1a2 1.472
Ppp1r3c 1.367 Prodh2 1.468
Cpxm1 1.366 Ap3m1 1.468
LOC100046254 1.365 Fbxo33 1.467
Junb 1.364 Slc25a42 1.467
2010311D03Rik 1.363 Qdpr 1.466
Krt8 1.363 Hbs1l 1.466
Angptl3 1.360 Pcsk4 1.465
Orm1 1.360 Tut1 1.465
Emp1 1.359 Sec14l4 1.465
Gca 1.359 Slc7a2 1.464
Nid1 1.358 Gstp1 1.464
Ddx3x 1.357 Glt25d1 1.464
Ebpl 1.354 Tmem160 1.464
Slc13a3 1.353 Smarca2 1.464
Btg1 1.353 Pxmp2 1.463
Tnip1 1.352 Zfp276 1.463
Tmem43 1.352 Nosip 1.463
Pparg 1.352 Cml1 1.463
Serinc2 1.351 Tmprss6 1.462
Col15a1 1.350 Scara5 1.462
LOC433801 1.350 Mup5 1.460
Cyp3a25 1.349 Cadps2 1.459
Gale 1.347 Rsn 1.459
Id2 1.347 EG665378 1.458
LOC668837 1.346 Pop5 1.458
Slc6a8 1.345 Igfbp4 1.456
Vim 1.345 Mbl1 1.455
Cd274 1.345 Rps25 1.455
Mfge8 1.342 Crcp 1.455
Tnfrsf19 1.342 Plxna1 1.454
Rnf125 1.341 Zfp771 1.454
Mlkl 1.341 Serpina1a 1.454
EG277333 1.340 Trfr2 1.453
Adam9 1.339 Foxo1 1.453
Pgrmc1 1.338 Dnajc3 1.452
Mat2a 1.337 LOC622404 1.452
Ccbl2 1.336 Sec63 1.451
Tnfaip2 1.336 Tmem150 1.451
Pip4k2a 1.335 Sepx1 1.451
Mad2l1 1.335 Slc6a12 1.451
Adra2b 1.334 Hist1h2bj 1.451
Snx7 1.333 Xpa 1.449
Chmp5 1.332 Syt1 1.448
Gsta4 1.331 Trap1 1.447
Pigp 1.330 Tnrc6a 1.446
Mreg 1.329 Ercc5 1.446
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Rnd3 1.329 Sil1 1.445
Nit2 1.328 9430029K10Rik 1.445
Cxadr 1.328 Gltpd2 1.445
Cotl1 1.323 Cxxc1 1.444
2900064A13Rik 1.323 Trp53inp2 1.443
Lrrc39 1.323 Serinc3 1.443
Dld 1.322 Trak1 1.443
Pmpcb 1.321 Arfgap2 1.443
Rab34 1.320 Iyd 1.442
Fas 1.320 Tnrc6c 1.442
Hist1h2ah 1.320 Hint2 1.442
Fen1 1.320 0610012G03Rik 1.442
Hsd17b11 1.320 Coq5 1.441
Tnxb 1.319 Gls2 1.441
Saa1 1.319 Rpain 1.439
Tnfrsf12a 1.317 Surf1 1.438
Acot2 1.317 Ube3b 1.437
Cd53 1.317 Mrps21 1.437
Entpd2 1.316 Eif4g1 1.436
Ermp1 1.315 Hamp 1.435
Cd86 1.315 Os9 1.435
Tapbp 1.315 Ganab 1.434
Cyp2c55 1.315 Mcm10 1.432
2610305D13Rik 1.314 Rab43 1.432
Ccl4 1.314 Rshl2a 1.431
1700047I17Rik1 1.314 Spg20 1.431
Snx3 1.313 Josd2 1.430
Mcm6 1.312 Cyp2c70 1.430
Ccdc120 1.310 Aldh16a1 1.428
Slc16a6 1.310 Vkorc1 1.428
Nipa1 1.308 Gorasp1 1.428
Arl2bp 1.308 Dap 1.427
1190002N15Rik 1.308 Pim3 1.426
Cryl1 1.308 Aox3 1.425
Litaf 1.307 Rps15 1.425
Jak1 1.306 Cyp27a1 1.425
Cdkn2c 1.306 2310007F21Rik 1.425
Rhod 1.306 Acy1 1.424
Bcl2l13 1.306 Mug2 1.424
Acot10 1.305 Stk11 1.424
Aifm1 1.303 Yif1b 1.424
Phca 1.303 Irf3 1.423
Arcn1 1.303 Fbxl10 1.423
Esr1 1.303 Rapgef4 1.423
Palld 1.301 Tm2d2 1.422
Ldlr 1.301 Serpinf2 1.422
Rab8b 1.300 Ceacam1 1.422
Csnk1g2 1.422
Hnrpc 1.421
Gpld1 1.421
Supplementary Table 1.Continued
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Hist1h2bh 1.421
Ssr4 1.421
Bst2 1.421
Acox2 1.421
Sra1 1.420
Cyp2c37 1.420
Eif4ebp2 1.420
Atp13a1 1.420
Abat 1.420
Per2 1.419
Polr2f 1.419
Slc1a2 1.419
Bckdhb 1.418
Itih1 1.418
Pbld 1.418
Fam134a 1.417
Lgals4 1.416
LOC100047856 1.416
LOC100044324 1.416
2900010M23Rik 1.415
Rnase4 1.415
Vtn 1.415
Mrpl17 1.414
Stat3 1.414
Ankzf1 1.414
5133401N09Rik 1.414
Prpf8 1.414
Bckdha 1.413
Sirt7 1.413
C1rl 1.413
Ndufb10 1.413
EG13909 1.413
Mug4 1.412
Gnmt 1.412
Bloc1s1 1.411
Cuta 1.411
Vrk3 1.411
Fetub 1.410
Lims2 1.409
Tm7sf2 1.407
Gltpd2 1.407
Ppap2b 1.407
Prei4 1.407
Arl3 1.407
A430005L14Rik 1.406
Rpl36a 1.406
Dnajc7 1.406
Map2k2 1.405
Dym 1.405
Wdr45l 1.404
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Plekhg3 1.404
Rps21 1.404
Ghr 1.403
Bmp1 1.403
Tle1 1.403
Ppargc1b 1.402
Acad10 1.402
Rpl12 1.402
Pnpo 1.401
Ddx3y 1.401
Galt 1.401
Smoc1 1.401
Cyp27a1 1.399
Clmn 1.399
3110056O03Rik 1.399
Tex264 1.399
Nat6 1.398
Pla2g12a 1.397
Srm 1.396
LOC100048020 1.396
Bat3 1.396
Tsc22d3 1.396
Mupcdh 1.396
Acat1 1.396
Cib1 1.396
Exosc5 1.396
1300007L22Rik 1.396
Sort1 1.394
LOC545056 1.394
Gtf3c1 1.392
Myo18a 1.392
LOC100048105 1.392
Csnk2a2 1.391
Csnk1g3 1.391
Serpinc1 1.391
Mrps28 1.391
Aamp 1.391
Tha1 1.391
Aars 1.390
Cope 1.390
Bri3 1.390
Nme3 1.389
Ppp1r3b 1.389
Ccdc84 1.389
Sirt3 1.388
1500032D16Rik 1.388
Mrps26 1.388
Ict1 1.387
Tpst1 1.387
Prpf38b 1.387
Supplementary Table 1.Continued
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Als2 1.387
Klkb1 1.387
MGC18837 1.386
Dcxr 1.386
1700029P11Rik 1.386
Gaa 1.385
1700012H05Rik 1.385
Gnl3 1.385
Hdgf 1.385
Aifm1 1.385
Tcf25 1.384
Sdc2 1.384
Mtss1 1.384
Atf2 1.384
Cyp2c67 1.383
Eef2 1.383
Mrpl2 1.383
Usp2 1.382
Timm10 1.382
Fkbp8 1.382
0610012D14Rik 1.382
3300001P08Rik 1.382
F12 1.381
2010100O12Rik 1.381
Slc26a1 1.381
Paox 1.380
Afmid 1.380
Dpp3 1.380
Dpm2 1.379
St3gal3 1.378
Serpina1a 1.378
2810428I15Rik 1.377
Akr7a5 1.377
6430527G18Rik 1.377
D19Wsu162e 1.376
Phb2 1.376
Trabd 1.376
Txnl4a 1.376
Macrod1 1.376
Gamt 1.375
Lgsn 1.374
Atp5g2 1.374
Jmjd6 1.373
Cyp27a1 1.373
Cno 1.373
Naprt1 1.372
Hpn 1.372
Il1rap 1.371
Rnf6 1.370
Atp1a1 1.370
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Yeats4 1.370
Lmf1 1.370
Bcas3 1.370
Echdc2 1.370
Acot12 1.370
Kng1 1.369
Hsd17b10 1.369
Upb1 1.369
D17Wsu92e 1.369
Taf10 1.369
Keap1 1.368
Pdcd5 1.368
Plekhb1 1.368
Mthfd1 1.368
Nr1h4 1.367
BC031181 1.366
Fpgs 1.366
Gphn 1.366
Ccar1 1.366
Stard5 1.366
Slc25a38 1.365
Ccdc21 1.365
Psmc5 1.364
C130074G19Rik 1.364
0610007P22Rik 1.364
Dalrd3 1.364
Mib2 1.363
Tsc2 1.363
Sec63 1.363
Myo6 1.362
Abtb1 1.362
1110008F13Rik 1.362
Tspan33 1.362
Mettl7b 1.361
LOC100048445 1.361
BC021381 1.361
H13 1.361
Zfp91 1.361
Arﬂ4 1.360
1810008A18Rik 1.359
Tlcd2 1.359
Ube2l3 1.359
6430706D22Rik 1.359
Prpf6 1.359
Cebpa 1.358
Tsta3 1.358
Aspscr1 1.358
Gphn 1.357
Ccnt1 1.357
Prox1 1.357
Supplementary Table 1.Continued
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Dph2 1.356
Nr1h2 1.356
Dcxr 1.355
Arg1 1.355
Per1 1.355
Cox4i1 1.355
1700021F05Rik 1.354
Masp2 1.354
9530058B02Rik 1.354
Sf3b5 1.353
Ctdsp1 1.353
Akap8l 1.352
Slc37a4 1.351
Rab18 1.351
Mrps34 1.351
Mfsd2 1.350
Ext2 1.350
Ttyh2 1.350
Dnajb2 1.350
Lsm12 1.349
Ddx24 1.349
Tmem201 1.349
Fh1 1.348
Cpn1 1.348
Cxxc1 1.348
Isy1 1.347
Srm 1.347
Ythdf1 1.347
Derl2 1.346
Csrp2 1.346
Gnmt 1.346
Mfn1 1.346
Igfbp4 1.345
Rnf166 1.345
LOC100048105 1.345
2700038C09Rik 1.345
Herpud1 1.345
Trfr2 1.344
BC056474 1.343
Mon1a 1.343
Itih4 1.343
Upf1 1.342
Rpl19 1.342
Gdi1 1.342
Echdc2 1.341
5730453I16Rik 1.340
Eif3g 1.340
Dgcr2 1.340
Fbxo34 1.340
Mett11d1 1.340
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Ngef 1.340
Fastk 1.340
Pex6 1.340
Dexi 1.340
Bclaf1 1.339
Use1 1.339
Zfp607 1.338
EG545056 1.338
Ugt2a3 1.338
Uspl1 1.337
Cope 1.337
Arrdc2 1.337
C1rl 1.336
Rabac1 1.336
Anp32a 1.336
Rilp 1.336
Prr14 1.336
620807 1.336
Limd1 1.335
Ctsf 1.335
Lemd2 1.335
Lamp2 1.335
Cldn3 1.335
Nol5 1.335
Man2c1 1.334
Scarb2 1.333
Igf1 1.333
S100a13 1.333
LOC100047937 1.333
Zbtb7a 1.332
Ogfod2 1.332
B3gnt1 1.332
Zbtb22 1.331
Atp6v0a1 1.331
Pnpla2 1.331
Plg 1.331
Sdhb 1.330
Cdo1 1.329
Ilvbl 1.329
6720456B07Rik 1.329
Map1lc3b 1.329
Smarca2 1.328
Fars2 1.328
Whdc1 1.328
1110032A13Rik 1.327
Dmwd 1.327
Morc3 1.327
Myg1 1.327
Scap 1.327
Itfg3 1.327
Supplementary Table 1.Continued
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1110007A13Rik 1.326
Cmtm8 1.326
Wipi2 1.326
1110007L15Rik 1.326
Vkorc1 1.326
Eif3eip 1.325
1810020D17Rik 1.325
Dexi 1.325
Rpl28 1.325
Slc6a9 1.324
Jmjd3 1.324
1300001I01Rik 1.324
Cog8 1.324
Irf3 1.324
Chmp2a 1.324
D19Bwg1357e 1.323
Itpr2 1.323
LOC100047935 1.323
H2-Ke6 1.323
Mrpl3 1.322
Mrpl34 1.322
Slc25a39 1.322
Spcs3 1.321
Dhrs4 1.321
Ppp1r9a 1.321
Nags 1.321
Keap1 1.321
Cox7a2l 1.320
Mocs1 1.320
Sap30l 1.320
C630028N24Rik 1.319
Zfand2b 1.319
LOC100045697 1.319
Pdcd2 1.318
Yipf3 1.318
Ctdsp1 1.318
Mrps9 1.318
Plg 1.317
Upb1 1.317
B020018G12Rik 1.317
Il1rap 1.317
Gchfr 1.316
Rab3gap1 1.316
Slc35e3 1.316
Rufy3 1.316
Tmem63b 1.316
Ndufv2 1.316
Pde4dip 1.315
Avpr1a 1.315
Ogfr 1.315
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Symbol Fold Up Symbol Fold Down
Tec 1.314
Golga2 1.314
Acads 1.314
Tnrc6a 1.314
Sbf1 1.314
Faah 1.314
1810026J23Rik 1.314
Arl3 1.313
Tmem14c 1.313
Brms1 1.313
Qprt 1.313
Atp5d 1.312
Slc2a9 1.312
Sdc4 1.312
Eif1b 1.311
Prdx4 1.311
Dmtf1 1.311
Il6st 1.311
Tmem204 1.311
Rnaseh2c 1.311
Aldh1l1 1.310
Fis1 1.310
Clcn2 1.310
Impdh2 1.310
Cdk8 1.309
Wdr45 1.309
Creb3l3 1.308
Aes 1.308
Riok3 1.308
Mta2 1.308
Slc12a2 1.308
Morf4l1 1.307
Trpc4ap 1.307
Tmem53 1.307
2310044H10Rik 1.307
Snrpd2 1.307
Cxcl12 1.306
Lcat 1.306
Depdc6 1.306
Imp3 1.306
2610003J06Rik 1.306
Proc 1.306
Fbxo34 1.305
Dbp 1.305
Etfb 1.305
Mrpl27 1.305
Bola2 1.305
Elof1 1.305
Cmtm8 1.305
Enpp1 1.305
Supplementary Table 1.Continued
Symbol Fold Up Symbol Fold Down
2410015M20Rik 1.304
Polr1a 1.304
Pih1d1 1.304
Xrcc6 1.304
Mbl2 1.304
Naca 1.304
F12 1.304
2310003H01Rik 1.303
Fxyd1 1.303
Tacc1 1.303
Gemin4 1.303
Slc1a2 1.303
Txn2 1.302
Gpt2 1.302
LOC100045782 1.302
Slc9a3r1 1.302
Elavl1 1.302
AA415398 1.301
Sox5 1.301
Tmem143 1.300
Rab8a 1.300
Atg2a 1.300
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Supplementary Table 2.Full List of Signiﬁcantly Enriched Canonical Pathways and Gene Ontology Categories Modulated
in PEDF Knockout Mice Livers
Up-Regulated Canonical Pathways [DATABASE_PATHWAY NAME]
Database Web Link: (http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection¼CP)
Name NES FDR q Value
KEGG_GLUTATHIONE_METABOLISM 2.329 <.001
PID_INTEGRIN1_PATHWAY 2.221 .003
REACTOME_COLLAGEN_FORMATION 2.168 .006
REACTOME_GLUTATHIONE_CONJUGATION 2.136 .008
REACTOME_NCAM1_INTERACTIONS 2.089 .013
PID_SYNDECAN_1_PATHWAY 2.080 .013
PID_FOXM1PATHWAY 2.099 .014
REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION 2.057 .016
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 2.010 .020
KEGG_ECM_RECEPTOR_INTERACTION 2.029 .021
KEGG_HEMATOPOIETIC_CELL_LINEAGE 2.013 .022
PID_AVB3_INTEGRIN_PATHWAY 1.986 .024
PID_NFAT_TFPATHWAY 1.979 .024
REACTOME_INTERFERON_ALPHA_BETA_SIGNALING 1.966 .024
KEGG_DRUG_METABOLISM_CYTOCHROME_P450 1.971 .025
KEGG_CELL_CYCLE 1.915 .032
KEGG_DNA_REPLICATION 1.918 .033
REACTOME_DNA_STRAND_ELONGATION 1.923 .033
PID_TOLL_ENDOGENOUS_PATHWAY 1.928 .034
PID_FRA_PATHWAY 1.879 .046
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 1.864 .049
Down-Regulated Canonical Pathways [DATABASE_PATHWAY NAME]
Database Web Link: (http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection¼CP)
Name NES FDR q Value
REACTOME_PEPTIDE_CHAIN_ELONGATION 2.878 <.001
REACTOME_TRANSLATION 2.873 <.001
REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION 2.840 <.001
REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION 2.827 <.001
KEGG_RIBOSOME 2.821 <.001
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCT_COMPLEX 2.797 <.001
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE 2.718 <.001
REACTOME_INFLUENZA_LIFE_CYCLE 2.571 <.001
REACTOME_METABOLISM_OF_MRNA 2.565 <.001
REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES 2.433 .005
REACTOME_METABOLISM_OF_RNA 2.434 .005
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX 2.416 .005
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX 2.419 .005
KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM 2.232 .049
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Up-Regulated Gene Ontology Categories
Database Web Link: (http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection¼C5)
Name NES FDR q Value
GLUTATHIONE_TRANSFERASE_ACTIVITY 2.041 .039
COLLAGEN 2.049 .071
CYTOKINE_ACTIVITY 1.907 .109
Down-Regulated Gene Ontology Categories
Database Web Link: (http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection¼C5)
Name NES FDR q Value
STRUCTURAL_CONSTITUENT_OF_RIBOSOME 2.790 <.001
MITOCHONDRIAL_PART 2.287 .048
AMINO_ACID_AND_DERIVATIVE_METABOLIC_PROCESS 2.185 .050
MITOCHONDRIAL_MATRIX 2.173 .051
PROTEASE_INHIBITOR_ACTIVITY 2.162 .051
CARBOXYLIC_ACID_METABOLIC_PROCESS 2.244 .052
REGULATION_OF_ANGIOGENESIS 2.198 .053
NITROGEN_COMPOUND_CATABOLIC_PROCESS 2.186 .053
MITOCHONDRION 2.292 .054
NITROGEN_COMPOUND_METABOLIC_PROCESS 2.215 .054
MITOCHONDRIAL_LUMEN 2.200 .056
SERINE_TYPE_ENDOPEPTIDASE_INHIBITOR_ACTIVITY 2.224 .056
ANATOMICAL_STRUCTURE_FORMATION 2.248 .056
MITOCHONDRIAL_ENVELOPE 2.023 .057
ORGANELLE_INNER_MEMBRANE 2.026 .059
AMINO_ACID_CATABOLIC_PROCESS 2.005 .059
RIBOSOME 2.031 .060
MITOCHONDRIAL_RIBOSOME 2.047 .060
RIBOSOMAL_SUBUNIT 2.250 .062
SPLICEOSOME 1.977 .062
DNA_DIRECTED_RNA_POLYMERASEII_HOLOENZYME 1.939 .062
MITOCHONDRIAL_MEMBRANE 2.048 .063
Note: FDR (false-discovery rate), FDR q value; NES, normalized enrichment score.
Supplementary Table 2. Continued
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Supplementary Table 3.Full List of Chemical and Genetic Perturbations That Were Signiﬁcantly Enriched in PEDF KO Mice
Livers
Up-Regulated Chemical and Genetic Perturbation Datasets
Up-Regulated List Truncated at FDR < .005
Database Web Link: (http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection¼CGP)
Name NES FDR q Value
LEE_LIVER_CANCER_ACOX1_UP 3.117 .000
LEE_LIVER_CANCER_E2F1_UP 3.017 .000
LEE_LIVER_CANCER_MYC_E2F1_UP 2.984 .000
LEE_LIVER_CANCER_MYC_TGFA_UP 2.911 .000
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_UP 2.892 .000
KHETCHOUMIAN_TRIM24_TARGETS_UP 2.891 .000
LEE_LIVER_CANCER_CIPROFIBRATE_UP 2.858 .000
LEE_LIVER_CANCER_DENA_UP 2.780 .000
WIELAND_UP_BY_HBV_INFECTION 2.772 .000
BORLAK_LIVER_CANCER_EGF_UP 2.742 .000
SERVITJA_LIVER_HNF1A_TARGETS_UP 2.742 .000
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM3 2.697 .000
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM2 2.635 .000
HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN 2.622 .000
DEMAGALHAES_AGING_UP 2.605 .000
POOLA_INVASIVE_BREAST_CANCER_UP 2.580 .000
HECKER_IFNB1_TARGETS 2.516 .000
BOYAULT_LIVER_CANCER_SUBCLASS_G5_DN 2.507 .000
MCLACHLAN_DENTAL_CARIES_DN 2.476 .000
LE_EGR2_TARGETS_UP 2.445 .000
HOSHIDA_LIVER_CANCER_SUBCLASS_S1 2.403 .000
KIM_GLIS2_TARGETS_UP 2.390 .000
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_UP 2.385 .000
ALTEMEIER_RESPONSE_TO_LPS_WITH_MECHANICAL_VENTILATION 2.374 .000
JOHANSSON_GLIOMAGENESIS_BY_PDGFB_UP 2.373 .000
MCBRYAN_PUBERTAL_TGFB1_TARGETS_DN 2.366 .000
STEARMAN_TUMOR_FIELD_EFFECT_UP 2.361 .000
BURTON_ADIPOGENESIS_3 2.357 .000
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP 2.355 .000
MCBRYAN_PUBERTAL_BREAST_4_5WK_UP 2.340 .000
ONDER_CDH1_TARGETS_2_DN 2.328 .000
MCBRYAN_PUBERTAL_BREAST_6_7WK_DN 2.322 .000
ISHIDA_E2F_TARGETS 2.297 .000
KORKOLA_TERATOMA 2.292 .000
LIU_VAV3_PROSTATE_CARCINOGENESIS_UP 2.290 .000
PASINI_SUZ12_TARGETS_DN 2.262 .001
MIKKELSEN_NPC_HCP_WITH_H3K27ME3 2.253 .001
CHANG_CYCLING_GENES 2.253 .001
MOSERLE_IFNA_RESPONSE 2.252 .001
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR 2.250 .001
BOYLAN_MULTIPLE_MYELOMA_C_D_DN 2.244 .001
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP 2.233 .001
WENG_POR_TARGETS_LIVER_UP 2.233 .001
KANG_DOXORUBICIN_RESISTANCE_UP 2.232 .001
ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_UP 2.231 .001
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Supplementary Table 3.Continued
Up-Regulated Chemical and Genetic Perturbation Datasets
Up-Regulated List Truncated at FDR < .005
Database Web Link: (http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection¼CGP)
Name NES FDR q Value
MCLACHLAN_DENTAL_CARIES_UP 2.229 .001
LENAOUR_DENDRITIC_CELL_MATURATION_UP 2.226 .001
BROWN_MYELOID_CELL_DEVELOPMENT_UP 2.222 .001
YAGI_AML_FAB_MARKERS 2.216 .001
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_UP 2.214 .001
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP 2.212 .001
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP 2.209 .001
YAMASHITA_METHYLATED_IN_PROSTATE_CANCER 2.195 .001
STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN 2.193 .001
GAL_LEUKEMIC_STEM_CELL_DN 2.193 .001
ODONNELL_TARGETS_OF_MYC_AND_TFRC_DN 2.188 .001
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP 2.186 .001
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP 2.163 .001
WALLACE_PROSTATE_CANCER_RACE_UP 2.163 .001
WHITFIELD_CELL_CYCLE_LITERATURE 2.162 .001
MORI_IMMATURE_B_LYMPHOCYTE_UP 2.159 .001
SMID_BREAST_CANCER_LUMINAL_B_DN 2.159 .001
CROONQUIST_NRAS_SIGNALING_DN 2.155 .001
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN 2.154 .001
CROONQUIST_IL6_DEPRIVATION_DN 2.151 .001
DELYS_THYROID_CANCER_UP 2.149 .001
MURATA_VIRULENCE_OF_H_PILORI 2.148 .001
LI_INDUCED_T_TO_NATURAL_KILLER_UP 2.144 .001
SERVITJA_ISLET_HNF1A_TARGETS_UP 2.131 .001
HAN_JNK_SINGALING_DN 2.129 .001
WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2 2.122 .001
BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN 2.119 .001
GOLDRATH_ANTIGEN_RESPONSE 2.119 .001
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR 2.115 .001
YU_MYC_TARGETS_UP 2.114 .001
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP 2.113 .001
RODWELL_AGING_KIDNEY_NO_BLOOD_UP 2.107 .001
LIAN_LIPA_TARGETS_3M 2.097 .002
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP 2.097 .002
SWEET_KRAS_TARGETS_UP 2.096 .002
TSAI_RESPONSE_TO_RADIATION_THERAPY 2.094 .002
MIKKELSEN_MCV6_HCP_WITH_H3K27ME3 2.094 .002
MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN 2.093 .002
RHODES_UNDIFFERENTIATED_CANCER 2.092 .002
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_DN 2.090 .002
HAN_JNK_SINGALING_UP 2.089 .002
AMIT_SERUM_RESPONSE_40_MCF10A 2.088 .002
WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_UP 2.087 .002
LIAN_LIPA_TARGETS_6M 2.086 .002
AKL_HTLV1_INFECTION_UP 2.081 .002
OKAMOTO_LIVER_CANCER_MULTICENTRIC_OCCURRENCE_UP 2.081 .002
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Supplementary Table 3.Continued
Up-Regulated Chemical and Genetic Perturbation Datasets
Up-Regulated List Truncated at FDR < .005
Database Web Link: (http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection¼CGP)
Name NES FDR q Value
LEE_EARLY_T_LYMPHOCYTE_UP 2.080 .002
LABBE_TARGETS_OF_TGFB1_AND_WNT3A_DN 2.080 .002
KATSANOU_ELAVL1_TARGETS_UP 2.079 .002
VANHARANTA_UTERINE_FIBROID_UP 2.074 .002
CHICAS_RB1_TARGETS_GROWING 2.073 .002
RODWELL_AGING_KIDNEY_UP 2.072 .002
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP 2.067 .002
ABRAHAM_ALPC_VS_MULTIPLE_MYELOMA_UP 2.067 .002
LIM_MAMMARY_LUMINAL_MATURE_DN 2.066 .002
KENNY_CTNNB1_ßTARGETS_UP 2.050 .002
BASAKI_YBX1_TARGETS_UP 2.046 .002
LIANG_SILENCED_BY_METHYLATION_UP 2.045 .002
CAVARD_LIVER_CANCER_MALIGNANT_VS_BENIGN 2.038 .003
KEEN_RESPONSE_TO_ROSIGLITAZONE_DN 2.036 .003
DAUER_STAT3_TARGETS_DN 2.035 .003
KAMMINGA_EZH2_TARGETS 2.032 .003
CHANG_IMMORTALIZED_BY_HPV31_DN 2.031 .003
KOBAYASHI_EGFR_SIGNALING_24HR_DN 2.027 .003
JEON_SMAD6_TARGETS_UP 2.022 .003
IGLESIAS_E2F_TARGETS_UP 2.017 .004
DAZARD_UV_RESPONSE_CLUSTER_G24 2.016 .004
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP 2.008 .004
ROSS_AML_WITH_CBFB_MYH11_FUSION 2.007 .004
URS_ADIPOCYTE_DIFFERENTIATION_DN 2.006 .004
DAZARD_RESPONSE_TO_UV_SCC_UP 2.006 .004
VERHAAK_AML_WITH_NPM1_MUTATED_UP 2.006 .004
GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP 2.004 .004
MEISSNER_BRAIN_HCP_WITH_H3K27ME3 2.001 .004
KAMIKUBO_MYELOID_CEBPA_NETWORK 1.998 .004
VERHAAK_GLIOBLASTOMA_NEURAL 1.997 .004
LIANG_SILENCED_BY_METHYLATION_2 1.992 .004
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_DN 1.989 .005
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP 1.980 .005
MCDOWELL_ACUTE_LUNG_INJURY_UP 1.974 .005
Down-Regulated Chemical and Genetic Perturbation Data Sets
Database Web Link: (http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection¼CGP)
Name NES FDR q Value
HSIAO_LIVER_SPECIFIC_GENES 2.829 .000
LEE_LIVER_CANCER_SURVIVAL_UP 2.743 .000
OHGUCHI_LIVER_HNF4A_TARGETS_DN 2.645 .000
BILANGES_SERUM_AND_RAPAMYCIN_SENSITIVE_GENES 2.596 .000
CAIRO_HEPATOBLASTOMA_DN 2.601 .000
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_DN 2.526 .001
BOYAULT_LIVER_CANCER_SUBCLASS_G3_DN 2.529 .001
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Supplementary Table 3.Continued
Down-Regulated Chemical and Genetic Perturbation Data Sets
Database Web Link: (http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection¼CGP)
Name NES FDR q Value
CHNG_MULTIPLE_MYELOMA_HYPERPLOID_UP 2.483 .003
SU_LIVER 2.408 .011
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4 2.351 .025
BOYAULT_LIVER_CANCER_SUBCLASS_G123_DN 2.327 .028
HOSHIDA_LIVER_CANCER_SUBCLASS_S3 2.331 .030
SERVITJA_LIVER_HNF1A_TARGETS_DN 2.310 .030
WOO_LIVER_CANCER_RECURRENCE_DN 2.314 .030
CAIRO_LIVER_DEVELOPMENT_DN 2.279 .039
LEE_LIVER_CANCER_ACOX1_DN 2.241 .051
Note: FDR (false-discovery rate) q value: adjusted P value; NES, normalized enrichment score.
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